What is Selank and why does its structure matter for analysis?
Selank is a synthetic heptapeptide analogue of the endogenous immunomodulatory fragment Tuftsin, characterised in the peptide-chemistry literature as a short, fully defined sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) studied extensively as a laboratory reference compound (Vyunova et al, 2018). From an analytical standpoint, the value of a short, non-disulfide-bonded, proline-rich sequence is that its theoretical monoisotopic and average masses can be calculated exactly and used as the primary identity target. The multiple proline residues influence chromatographic retention and can produce cis/trans conformer effects that manifest as peak shape features during RP-HPLC, so method developers must account for these when integrating a chromatogram. Because Selank contains no cysteine, identity confirmation does not require disulfide-mapping steps used for more complex peptides; instead the analytical burden centres on confirming the correct amino-acid composition, sequence order and the absence of process-related impurities. Establishing the exact molecular formula first is essential because every downstream measurement — the expected [M+H]+ and multiply-charged ions in ESI-MS, the predicted b/y fragment series in tandem MS, and the theoretical net peptide content after counterion correction — is referenced against that structure. A batch record therefore begins by stating the declared sequence, molecular formula and calculated mass so that all subsequent data can be cross-checked. Any deviation between observed and theoretical mass, or an unexpected retention profile, signals the need for further investigation before the material is considered characterised. This structural anchoring is the foundation of the entire QC workflow and distinguishes genuine characterisation from a simple label.
How is Selank chromatographic purity assessed by RP-HPLC?
Reversed-phase HPLC is the workhorse technique for estimating the chromatographic purity of a synthetic peptide such as Selank. In a typical configuration a C18 stationary phase is used with a water/acetonitrile gradient containing an ion-pairing modifier (commonly trifluoroacetic acid), and detection is performed by UV absorbance in the low-UV region (around 210–220 nm) where the peptide bond absorbs. Purity is reported as the area percentage of the main peak relative to total integrated peak area, and analytical guidance for high-purity materials emphasises that the chosen method must actually resolve related impurities from the main component for the number to be meaningful (Sudersanan, 2002). A single sharp peak alone is insufficient evidence of purity; co-eluting species can hide beneath a symmetrical peak. This is why peak-purity assessment — using diode-array spectral comparison across the peak or orthogonal method conditions — is applied to detect hidden co-elution. Method parameters that should appear in documentation include column chemistry and dimensions, gradient composition and time, flow rate, injection amount, detection wavelength and the integration approach. For Selank specifically, the proline-driven conformer behaviour means analysts should confirm that apparent shoulders are conformational rather than distinct impurities, often by verifying identical mass across the feature. Acceptance criteria for research-grade peptides are commonly set at a defined minimum main-peak area percentage with individual and total impurity limits stated separately. Reporting purity without disclosing the method and its resolving power is a red flag when evaluating a batch report. A defensible RP-HPLC result pairs a stated method with a chromatogram, retention time, and integrated area table so the researcher can independently interpret the data rather than trusting a headline percentage.
How does mass spectrometry confirm Selank identity and composition?
Mass spectrometry provides the identity confirmation that complements HPLC purity. Electrospray ionisation mass spectrometry (ESI-MS) ionises the peptide gently, producing protonated molecular ions from which the measured mass is compared against the theoretical value calculated from the declared Selank sequence. Foundational analytical work established ESI-MS as a rapid, high-throughput approach for both estimating purity and characterising synthetic peptide preparations, including the ability to detect deletion sequences and other synthesis by-products within a mixture (Smart et al, 1996). Earlier tandem-MS studies of synthetic multicomponent peptide mixtures demonstrated that composition and purity can be determined by combining accurate mass measurement with fragmentation analysis (Metzger et al, 1994). For Selank, a correct average or monoisotopic mass within the method's stated tolerance is the first identity checkpoint. However, mass alone does not prove sequence order, because isomeric or transposed sequences can share the same mass. Tandem MS (MS/MS) addresses this by fragmenting the peptide backbone to generate b- and y-ion series whose masses map to specific residue positions; matching the observed fragment ladder to the predicted series confirms the Thr-Lys-Pro-Arg-Pro-Gly-Pro order. Documentation should therefore state the instrument type, ionisation mode, observed versus theoretical mass, the mass tolerance applied, and — where sequence verification is claimed — the annotated fragment assignments. Together, intact-mass ESI-MS and MS/MS sequencing constitute orthogonal identity evidence that is far stronger than either technique alone, and they pair naturally with the HPLC purity number to give a complete picture of what is in the vial.
What impurities and related substances appear in synthetic Selank?
Solid-phase peptide synthesis of a sequence like Selank can introduce a characteristic family of process-related impurities that a thorough characterisation seeks to profile. These include deletion sequences (where a residue coupling failed), truncated chains, incomplete deprotection products, and adducts arising from the synthesis and purification chemistry. Combining chromatographic separation with mass detection allows many of these to be individually identified rather than merely counted, since each impurity often carries a diagnostic mass shift relative to the target peptide — for example, a mass difference corresponding to a missing residue points to a specific deletion sequence (Smart et al, 1996; Metzger et al, 1994). A related-substances analysis therefore reports not only a total impurity percentage but, where possible, the identity and level of individual named impurities against defined limits. A further consideration specific to peptides purified by reversed-phase methods using trifluoroacetic acid is the residual counterion: TFA associates with basic residues such as the arginine and lysine in Selank, contributing to the salt mass of the isolated solid. This matters because gravimetric mass overstates the true peptide content unless a net-peptide-content correction is applied. Analytical guidance on characterising high-purity materials stresses the role of complementary techniques to fully describe a substance rather than relying on a single measurement (Sudersanan, 2002). For documentation purposes, a rigorous Selank batch record distinguishes chromatographic purity (area %) from net peptide content (mass basis), reports water content where relevant, and notes the counterion. Researchers evaluating a supplier should look for this separation of concepts, because conflating purity with content is a common source of confusion and can mislead quantitative work in the laboratory.
How should a researcher read a Selank certificate of analysis?
A certificate of analysis (COA) is the summary document that consolidates identity, purity and supporting data for a specific Selank lot. Reading one critically means checking that the declared sequence and molecular formula are present, that the reported HPLC purity is accompanied by the method conditions and a chromatogram, and that a mass-spectrometry result lists observed versus theoretical mass with a tolerance. Each numeric result should carry a stated acceptance criterion so the researcher can see whether the batch passed a predefined threshold rather than an arbitrary one. Lot-release testing frameworks describe how a batch is sampled and assessed against fixed criteria before it is released, and a transparent COA reflects that logic by tying each test to its limit. Traceability elements — lot number, manufacture or test date, analytical method references and the identity of the testing arrangement — link the certificate back to the physical material and to the underlying raw data. Where a supplier provides both a comparative and product-specific report, the researcher can cross-reference the intact-mass and fragment data (see sequence-verification documentation) against the RP-HPLC purity figure. Additional parameters that strengthen a research-grade record include water content by Karl Fischer, residual counterion information and appearance. Importantly, a COA in a research-only context is an analytical statement about chemical identity and quality; it makes no representation about biological outcomes. When a certificate omits method detail, quotes purity without a chromatogram, or provides no acceptance criteria, those gaps should prompt caution. The strongest documentation lets an independent reviewer reconstruct the reasoning from raw data to conclusion, which is the standard ClaraScience applies to its Selank batch records for Australian research customers.
What stability and documentation practices support Selank characterisation?
Characterisation is not a one-time event; the analytical profile of Selank must remain valid through storage and handling, so stability-indicating practice and documentation are part of the same quality system. Peptides can undergo degradation pathways such as oxidation, hydrolysis and aggregation, and the presence of oxidation-sensitive or hydrolysis-prone motifs is one reason lyophilised material is generally stored cold and reconstituted only when required. A stability-aware programme uses the same RP-HPLC and MS methods described above to compare a stored or reconstituted sample against the release profile, looking for new impurity peaks or mass shifts that indicate change. Documentation should therefore record storage conditions, the lyophilisation state of the supplied solid, and any recommended handling for research use. Cold-chain records and lot traceability connect the analytical certificate to the physical logistics, which is particularly relevant for an Australian vendor shipping temperature-sensitive material. From a quality-systems perspective, retaining raw chromatograms, mass spectra, integration reports and the calculation of net peptide content creates an auditable trail that allows any result to be reconstructed and reviewed. This depth of record-keeping distinguishes rigorous research supply from unsupported labelling. It also allows researchers to interpret discrepancies — for example distinguishing a genuine impurity from a proline conformer or a solvent adduct — by referring back to method context. Throughout, the framing remains analytical and research-only: the objective is to describe and preserve the chemical identity and purity of the material, not to imply any physiological effect. Consistent, transparent documentation is ultimately what lets a laboratory place confidence in the Selank material it selects.
Order Selank with documentation
If this guide helped you evaluate Selank for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Selank card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What analytical techniques characterise Selank purity?
Reversed-phase HPLC estimates chromatographic purity as main-peak area percentage, while electrospray and tandem mass spectrometry confirm the peptide's mass and sequence order. Used together these orthogonal methods establish both identity and purity, and are documented on the certificate of analysis for research-use-only Selank material.
Why is HPLC purity different from net peptide content?
HPLC purity is the area-percentage of the main peak relative to total peaks, describing chromatographic homogeneity. Net peptide content is a mass-basis figure that subtracts water and counterions such as residual TFA. A batch can show high chromatographic purity yet a lower net peptide content, so both should be reported separately.
How does mass spectrometry confirm the Selank sequence?
Intact-mass ESI-MS compares the observed molecular ion to the theoretical mass of the declared sequence. Tandem MS then fragments the backbone into b- and y-ion series whose masses map to residue positions, confirming the Thr-Lys-Pro-Arg-Pro-Gly-Pro order rather than an isomeric sequence of identical mass.
What should a Selank certificate of analysis include?
A robust COA states the declared sequence and molecular formula, HPLC purity with method conditions and a chromatogram, observed versus theoretical mass with tolerance, impurity limits, net peptide content, water content, lot number and test date, and defined acceptance criteria for each result.
Does this analytical information describe any effect of Selank?
No. This content is strictly analytical and applies to research-use-only material. It describes chemical identity, purity, stability and documentation practices only. It makes no claims about biological, therapeutic or physiological effects and does not provide any usage guidance.
References
- DOI:10.2174/0929866525666180925144642 — Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity — Protein & Peptide Letters — 2018
- DOI:10.1111/j.1399-3011.1996.tb00809.x — High‐throughput purity estimation and characterisation of synthetic peptides by electrospray mass spectrometry — International Journal of Peptide and Protein Research — 1996
- DOI:10.1006/abio.1994.1266 — Electrospray Mass Spectrometry and Tandem Mass Spectrometry of Synthetic Multicomponent Peptide Mixtures: Determination of Composition and Purity — Analytical Biochemistry — 1994
- DOI:10.1016/s0960-8974(02)00017-7 — Role of analytical techniques for characterisation of advanced and high purity materials — Progress in Crystal Growth and Characterization of Materials — 2002
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
